Last updated: February 13, 2026
mmary
The drug with NDC 25021-0814 is Tepezza (teprotumumab-trbw), approved by the FDA on January 21, 2020. It’s indicated for treating active thyroid eye disease (TED). Currently, Tepezza's market is expanding driven by increasing diagnoses and ongoing demand, with potential for price adjustments based on market dynamics, reimbursement policies, and competitive developments.
What is the current market position of Tepezza (NDC 25021-0814)?
Tepezza is a monoclonal antibody targeting IGF-1 receptor, marketed by Horizon Therapeutics. It stands as the first and only FDA-approved treatment for TED. As of 2023, Tepezza maintains a dominant position in the niche therapy segment for thyroid eye disease.
- Sales Data: U.S. sales reached approximately $1.5 billion in 2022, with a projected increase over the next five years.
- Market Penetration: Estimated to be prescribed for about 80-90% of eligible TED patients based on survey data and prescription tracking.
- Pricing: The average wholesale price (AWP) per infusion is approximately $22,000, with typical treatment courses requiring 8 infusions.
How does the pricing of Tepezza compare to similar therapies?
Tepezza's cost surpasses traditional corticosteroids and orbital radiation therapies. Its per-course cost (approximately $176,000) reflects its specialty drug status and high efficacy profile.
| Parameter |
Tepezza |
Competitors (if any) |
Remarks |
| Per course (8 infusions) |
$176,000 |
No direct alternatives approved for TED |
Market leader in indication |
| Monthly treatment cost |
$22,000 |
N/A |
Only approved therapy for TED |
| Average wholesale price (AWP) |
$22,000 per infusion |
N/A |
NDC-specific pricing |
No direct competitors have received FDA approval for TED as of 2023; off-label treatments include corticosteroids and radiation, generally less costly but also less effective for active disease.
What are the price projection factors for Tepezza?
Pricing projections depend on multiple factors:
Market Expansion: Increasing diagnosis rates of TED, accelerated by heightened awareness and improved diagnostic tools. Estimated growth rate is 10-15% annually in the U.S. for new prescriptions.
Reimbursement Policies: Insurance coverage has remained favorable, but reimbursement thresholds and prior authorization requirements could influence net prices. Provider negotiations and formulary placements are crucial.
Market Competition: Currently, Tepezza enjoys exclusivity for TED; however, biopharma pipeline developments may challenge its dominance in future years. Any new entrants or biosimilar developments would pressure prices downward.
Regulatory and Policy Environment: Price regulation efforts, including Potential Medicare negotiation, could impact drug list prices.
Patent Status: Patent expiry is expected around 2030, which may lead to biosimilar development and price competition afterward.
Pricing Trends: Historically, specialty drugs maintain high prices initially that decline over time as biosimilars or generics enter the market or as payers negotiate discounts.
What are the expectations for future pricing?
- Short-term (1-2 years): Prices are expected to remain stable. Reimbursement pressures are currently manageable, and market penetration continues to grow.
- Mid-term (3-5 years): Price reductions of 10-15% may occur as biosimilars or alternative treatments develop and potentially reach approval. Payer negotiations could further dampen net prices.
- Long-term (post-2030): As patent protections lapse, biosimilars could lower list prices by 30-50%, similar to the pattern observed with other biologics like Humira.
What risks could affect the market outlook?
- Emergence of Biosimilars: Pending patent expiry, biosimilar development could reduce prices and market share.
- Regulatory Changes: Price negotiation policies, especially from Medicare, may pressure list prices.
- Market Competition: Lack of other approved therapies for TED lends dominance to Tepezza currently, but pipeline drugs or new indications could alter this dynamic.
- Reimbursement and Access: Coverage restrictions or high patient cost-sharing could limit market expansion.
Key Takeaways
- Tepezza remains the market leader for TED with high current pricing and growing prescription volume.
- Prices are expected to stabilize short-term but may decline 10-15% within 3-5 years due to biosimilar entry and payer negotiation.
- Long-term price pressure is likely post-patent expiry, potentially dropping list prices by half.
- Market expansion is contingent on diagnosis rates and reimbursement policies, influencing potential revenue growth.
- Future therapeutic developments pose a notable risk to Tepezza’s market dominance.
FAQs
1. What is the expected patent expiry date for Tepezza?
Patent protections are expected to last until roughly 2030, after which biosimilar competition may arise.
2. How does reimbursement impact Tepezza’s pricing?
Insurance coverage and negotiated discounts influence net prices, but current reimbursement policies favor high-cost biologics for TED.
3. Are there any biosimilars in development for teprotumumab?
As of early 2023, biosimilar development is underway but has not yet secured FDA approval.
4. What are the primary drivers of Tepezza’s revenue growth?
Increasing diagnosis rates of active TED and expanding access drive revenue, assuming stable pricing and reimbursement.
5. How does Tepezza compare to off-label treatments?
No approved alternatives are comparable; off-label corticosteroids are less costly but less effective and associated with different side-effect profiles.
Sources:
- FDA Approval Announcement, January 2020
- Horizon Therapeutics Q4 2022 Earnings Report
- IQVIA National Prescription Audit, 2022
- Market research reports on thyroid eye disease, 2023
- U.S. patent database, 2023
Note: All data are subject to change as market conditions evolve and new information becomes available.
